retatrutide + tirzepatide

retatrutide + tirzepatide is a combination regimen of two investigational and/or approved peptide-based drugs designed for the treatment of obesity and type 2 diabetes. Both drugs are multi-agonist analogs that target incretin hormone pathways to enhance glycemic control and promote weight loss. **Retatrutide** is a triple agonist, activating the glucagon-like peptide 1 receptor (GLP-1), glucose-dependent insulinotropic polypeptide receptor (GIP), and glucagon receptor. **Tirzepatide** is a dual agonist of the GLP-1 and GIP receptors. The synergy of combining these drugs is hypothesized to yield enhanced suppression of appetite, increased energy expenditure, and superior glycemic control relative to either agent alone. Retatrutide is not yet approved and is still under clinical investigation, whereas tirzepatide is FDA-approved for both type 2 diabetes and weight management[1][3][9].